Latest RNA reports update at 2024-05-09: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Avidity Biosciences RNA

$ 38.95 -1.79%

Avidity Biosciences Balance Sheet 2011-2024 | RNA

Annual Balance Sheet Avidity Biosciences

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-175 M	-330 M	-309 M	-	-90 M	7.23 M	-	-	-	-	-	-	-
Long Term Debt	6.21 M	7.58 M	9.96 M	-	1.77 M	7.58 M	-	-	-	-	-	-	-
Long Term Debt Current	3.64 M	3.1 M	1.77 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	152 M	40.5 M	-	-	-	-	-	-	-
Total Current Liabilities	80.7 M	51.9 M	29.7 M	14.6 M	-	-	-	-	-	-	-	-	-
Total Liabilities	128 M	60.7 M	46.2 M	27.7 M	162 M	45.1 M	-	-	-	-	-	-	-
Deferred Revenue	28.4 M	5.04 M	4.86 M	3.69 M	3.84 M	-	-	-	-	-	-	-	-
Retained Earnings	-571 M	-359 M	-185 M	-66.5 M	-22.2 M	-41.6 M	-	-	-	-	-	-	-
Total Assets	629 M	639 M	428 M	334 M	96.9 M	3.98 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	185 M	340 M	321 M	322 M	-	-	-	-	-	-	-	-	-
Book Value	501 M	578 M	381 M	306 M	-65.4 M	-41.1 M	-	-	-	-	-	-	-
Total Shareholders Equity	501 M	578 M	381 M	306 M	-65.4 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Avidity Biosciences

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	5.42 M	6.21 M	6.98 M	6.36 M	6.98 M	7.58 M	8.18 M	8.75 M	9.35 M	9.96 M	877 K	914 K	951 K	938 K	-	-	938 K	1.77 M	1.77 M	1.77 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	121 M	128 M	55.7 M	51.6 M	55.1 M	60.7 M	53.6 M	46.4 M	45.4 M	46.2 M	31 M	26 M	28.6 M	27.7 M	27.7 M	27.7 M	27.7 M	27.5 M	27.5 M	27.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	26.1 M	28.4 M	1.97 M	3.81 M	5.06 M	5.04 M	5.45 M	5.38 M	5.31 M	4.86 M	4.26 M	4.5 M	4.36 M	3.69 M	3.69 M	3.69 M	3.69 M	3.84 M	3.84 M	3.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-640 M	-571 M	-510 M	-458 M	-411 M	-359 M	-308 M	-264 M	-219 M	-185 M	-146 M	-117 M	-90.4 M	-66.5 M	-66.5 M	-66.5 M	-66.5 M	-22.2 M	-22.2 M	-22.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	951 M	629 M	573 M	611 M	614 M	639 M	431 M	421 M	421 M	428 M	426 M	291 M	315 M	334 M	334 M	334 M	334 M	96.9 M	96.9 M	96.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	471 M	185 M	85.6 M	154 M	119 M	340 M	144 M	125 M	140 M	320 M	410 M	276 M	301 M	321 M	321 M	321 M	321 M	94.6 M	94.6 M	94.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	831 M	501 M	517 M	559 M	559 M	578 M	377 M	374 M	376 M	381 M	395 M	264 M	286 M	306 M	306 M	306 M	306 M	69.4 M	69.4 M	69.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	831 M	501 M	517 M	559 M	559 M	578 M	377 M	374 M	376 M	381 M	395 M	264 M	286 M	306 M	306 M	306 M	306 M	-65.4 M	-65.4 M	-65.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency